2025 Annual Meeting | Exhibit Hall Presentation Stage Date Monday 04/07/25 Time 12:00 PM - 04:00 PM PDT Add To Calendar Location San Diego Convention Center | Exhibit Hall BCD Session Format This program will be presented in-person only On Demand This program is not expected to be available in the meeting's On Demand product. Event Type Other Topic(s) General Neurology Learning Objectives Join us at the Exhibit Hall Presentation Stage for today’s presentations and performances!12:30PM - 12:50PM Presentation by: Grifols Shared Services North AmericaHow Do I Treat CIDP?A case presentation of a 45-year-old man who reported progressive arm and leg weakness. Dr. Muley will walk through his decision making process for diagnosis and treatment including consideration of new modalities for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP).Speaker: Dr. Suraj Muley 3:00PM - 3:20PM Presentation by: C2N DiagnosticsTransforming Alzheimer’s Disease Diagnosis with The PrecivityAD2 Blood Test: Seeking to Establish a New Clinical Care Standard for Patients with Memory ImpairmentThe PrecivityAD2™ blood test is a breakthrough in Alzheimer’s disease diagnosis, offering high concordance with amyloid PET scan and CSF biomarkers to identify brain amyloid pathology. This test uses high-resolution mass spectrometry and multiple proteomic analysis to facilitate an early and accurate diagnosis for patients with cognitive impairment. The discussion will revolve around how the PrecivityAD2 test and other emerging molecular tools are redefining clinical care pathways in neurological medicine.Speaker: Sheena Aurora, MD, VP of Neurology, C2N Diagnostics 3:30pm - 3:50pm Presentation by: ARUP LaboratoriesInnovative Insights: Clinical and Analytical Performance of the Plasma p-Tau217 Quanterix SP-X Chemiluminescent AssayARUP Labs presents about the Quanterix SP-X Human p-Tau217 assay. Topics covered include: Clinical comparison to Aβ positron emission tomography (PET) using Fluorbetapir (FBP) in 524 patient samples derived from a cohort with disease prevalence of 65%; assay performance characteristics including method comparison, analyte recovery, precision, analytical sensitivity, analyte stability, and interference/cross-reactivity.Speakers: Leo Lin, MD, PhD and Kelly Doyle, PhD, DABCC, FADLM 4:00 PM - 6:00 PM Live Music from AAN Member! CME Available No CME available Program Materials Program Evaluations Event Timeline 12:00 PM - 04:00 PM PDT Speaker Exhibit Hall Presentation Stage Faculty Disclosures